{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:44:14Z","timestamp":1792089854223,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Major Science and Technology Projects in Guangxi","award":["AB25069013"],"award-info":[{"award-number":["AB25069013"]}]},{"name":"Liuzhou Science and Technology Plan Project","award":["2020NBAD0802"],"award-info":[{"award-number":["2020NBAD0802"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-026-00924-y","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:46:52Z","timestamp":1784299612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment HIV-1 drug resistance and molecular subtype characteristics among newly diagnosed individuals in Guangxi, China"],"prefix":"10.1186","volume":"23","author":[{"given":"Guibin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"924_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12992-025-01181-w","volume":"22","author":"Y Assefa","year":"2025","unstructured":"Assefa Y, et al. The successful scaling-up of antiretroviral therapy globally has many lessons for advancing universal health coverage: progress at risk. Glob Health. 2025;22(1):16.","journal-title":"Glob Health"},{"issue":"4","key":"924_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.35772\/ghm.2023.01013","volume":"5","author":"AK Ghosh","year":"2023","unstructured":"Ghosh AK. Four decades of continuing innovations in the development of antiretroviral therapy for HIV\/AIDS: progress to date and future challenges. Glob Health Med. 2023;5(4):194\u20138.","journal-title":"Glob Health Med"},{"issue":"8","key":"924_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160460","volume":"11","author":"A Trickey","year":"2016","unstructured":"Trickey A, et al. Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. PLoS ONE. 2016;11(8):e0160460.","journal-title":"PLoS ONE"},{"key":"924_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040915","author":"MM Apetroaei","year":"2024","unstructured":"Apetroaei MM, et al. The phenomenon of antiretroviral drug resistance in the context of human immunodeficiency virus treatment: dynamic and ever evolving subject matter. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12040915.","journal-title":"Biomedicines"},{"key":"924_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jgar.2022.01.017","volume":"28","author":"R Li","year":"2022","unstructured":"Li R, et al. Prevalence of transmitted drug resistance among ART-na\u00efve HIV-infected individuals, Beijing, 2015\u20132018. J Glob Antimicrob Resist. 2022;28:241\u20138.","journal-title":"J Glob Antimicrob Resist"},{"key":"924_CR6","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/IDR.S516513","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. Impact of HIV pretreatment drug resistance on secondary transmission through treatment dropout: a prospective population-based study in Southwestern China. Infect Drug Resist. 2025;18:2311\u201327.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"924_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1468-1293.2008.00562.x","volume":"9","author":"A Apisarnthanarak","year":"2008","unstructured":"Apisarnthanarak A, et al. Antiretroviral drug resistance among antiretroviral-na\u00efve persons with recent HIV infection in Thailand. HIV Med. 2008;9(5):322\u20135.","journal-title":"HIV Med"},{"issue":"12","key":"924_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1089\/aid.2016.0143","volume":"32","author":"M Escoto-Delgadillo","year":"2016","unstructured":"Escoto-Delgadillo M, et al. HIV drug resistance in antiretroviral-naive patients in Mexico after 10 years: is there a difference? AIDS Res Hum Retroviruses. 2016;32(12):1219\u201322.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"7","key":"924_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/QAD.0000000000003182","volume":"36","author":"LE Hermans","year":"2022","unstructured":"Hermans LE, et al. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment. AIDS. 2022;36(7):923\u201331.","journal-title":"AIDS"},{"issue":"1","key":"924_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12985-025-02734-6","volume":"22","author":"J Li","year":"2025","unstructured":"Li J, et al. Characteristics of molecular epidemiology and transmitted drug resistance among newly diagnosed HIV-1 infections in Lishui, China from 2020 to 2023. Virol J. 2025;22(1):111.","journal-title":"Virol J"},{"issue":"1","key":"924_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2373105","volume":"15","author":"M Zhang","year":"2017","unstructured":"Zhang M, et al. Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017\u20132021. Virulence. 2017;15(1):2373105.","journal-title":"Virulence"},{"key":"924_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2023.105520","volume":"115","author":"J Liu","year":"2023","unstructured":"Liu J, et al. Increased prevalence of pretreatment drug resistance mutations in treatment-na\u00efve people living with HIV-1 in Henan Province, China (2022\/23). Infect Genet Evol. 2023;115:105520.","journal-title":"Infect Genet Evol"},{"issue":"3","key":"924_CR13","first-page":"161","volume":"18","author":"W Lyu","year":"2025","unstructured":"Lyu W, Cai W, Chen Y, Han M, He Y, Li H, et al. Expert consensus on HIV drug resistance testing and clinical management. Chin J Clin Infect Dis. 2025;18(3):161\u201371.","journal-title":"Chin J Clin Infect Dis"},{"issue":"10","key":"924_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03149-24","volume":"13","author":"T Huang","year":"2025","unstructured":"Huang T, et al. Molecular epidemiology and pretreatment drug resistance of HIV-1 among newly diagnosed individuals in Nanning City, Guangxi, China. Microbiol Spectr. 2025;13(10):e0314924.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"924_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12981-020-00264-5","volume":"17","author":"P Liu","year":"2020","unstructured":"Liu P, et al. HIV drug resistance in patients in China\u2019s national HIV treatment programme who have been on first-line ART for at least 9 months. AIDS Res Ther. 2020;17(1):9.","journal-title":"AIDS Res Ther"},{"key":"924_CR16","doi-asserted-by":"publisher","first-page":"6657112","DOI":"10.1155\/2021\/6657112","volume":"2021","author":"J Zhu","year":"2021","unstructured":"Zhu J, et al. Mortality and attrition rates within the first year of antiretroviral therapy initiation among people living with hiv in Guangxi, China: an observational cohort study. Biomed Res Int. 2021;2021:6657112.","journal-title":"Biomed Res Int"},{"issue":"13","key":"924_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/QAD.0000000000003288","volume":"36","author":"K Huik","year":"2022","unstructured":"Huik K, et al. High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy. AIDS. 2022;36(13):1835\u201340.","journal-title":"AIDS"},{"issue":"27","key":"924_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Med. 2021;385(27):2531\u201343.","journal-title":"N Engl J Med"},{"key":"924_CR19","unstructured":"WHO, WHO recommends dolutegravir as preferred HIV treatment option in all populations. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations, 2019: p. Accessed June 2, 20126."},{"issue":"1","key":"924_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12981-020-00264-5","volume":"17","author":"P Liu","year":"2020","unstructured":"Liu P, et al. HIV drug resistance in patients in China\u2019s national HIV treatment programme who have been on first-line ART for at least 9 months. AIDS Res Ther. 2020;17(1):9.","journal-title":"AIDS Res Ther"},{"issue":"4","key":"924_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/pathogens14040336","volume":"14","author":"Q Su","year":"2025","unstructured":"Su Q, et al. The prevalence of pretreatment drug resistance and transmission networks among newly diagnosed HIV-1-infected individuals in Nanning, Guangxi, China. Pathogens. 2025;14(4):336.","journal-title":"Pathogens"},{"issue":"1","key":"924_CR22","doi-asserted-by":"publisher","first-page":"6775","DOI":"10.1038\/s41598-020-63731-z","volume":"10","author":"GM Nduva","year":"2020","unstructured":"Nduva GM, et al. HIV-1 transmission patterns within and between risk groups in coastal Kenya. Sci Rep. 2020;10(1):6775.","journal-title":"Sci Rep"},{"issue":"2","key":"924_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/infdis\/jit524","volume":"209","author":"JO Wertheim","year":"2014","unstructured":"Wertheim JO, et al. The global transmission network of HIV-1. J Infect Dis. 2014;209(2):304\u201313.","journal-title":"J Infect Dis"},{"issue":"1","key":"924_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12879-024-09337-6","volume":"24","author":"H Shi","year":"2024","unstructured":"Shi H, et al. Molecular transmission network analysis of newly diagnosed HIV-1 infections in Nanjing from 2019 to 2021. BMC Infect Dis. 2024;24(1):583.","journal-title":"BMC Infect Dis"},{"key":"924_CR25","doi-asserted-by":"publisher","first-page":"1701408","DOI":"10.3389\/fmicb.2025.1701408","volume":"16","author":"Y-Q Yin","year":"2025","unstructured":"Yin Y-Q, et al. Molecular transmission network analysis of newly diagnosed HIV-1 infections in Ningbo from 2018\u20132022. Front Microbiol. 2025;16:1701408.","journal-title":"Front Microbiol"},{"key":"924_CR26","doi-asserted-by":"publisher","first-page":"1716273","DOI":"10.3389\/fimmu.2025.1716273","volume":"16","author":"D Wang","year":"2025","unstructured":"Wang D, et al. Molecular transmission network characteristics and high-risk transmission analysis of newly reported HIV-1 subjects in Nantong, China. Front Immunol. 2025;16:1716273.","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"924_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/135965350801302S04","volume":"13","author":"DE Bennett","year":"2008","unstructured":"Bennett DE, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25\u201336.","journal-title":"Antivir Ther"},{"issue":"53","key":"924_CR28","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.46234\/ccdcw2021.251","volume":"3","author":"J Hao","year":"2021","unstructured":"Hao J, et al. Changing proportions of HIV-1 subtypes and transmitted drug resistance among newly diagnosed HIV\/AIDS individuals\u2014China, 2015 and 2018. China CDC Wkly. 2021;3(53):1133\u20138.","journal-title":"China CDC Wkly"},{"issue":"4","key":"924_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/1570162X20666220613120735","volume":"20","author":"J Yang","year":"2022","unstructured":"Yang J, et al. Post-lockdown rebounding high-risk behaviors and HIV testing among MSM in China in the era of the COVID-19 pandemic. Curr HIV Res. 2022;20(4):287\u201395.","journal-title":"Curr HIV Res"},{"issue":"4","key":"924_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","volume":"12","author":"RL Hamers","year":"2012","unstructured":"Hamers RL, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12(4):307\u201317.","journal-title":"Lancet Infect Dis"},{"issue":"suppl_9","key":"924_CR31","doi-asserted-by":"publisher","first-page":"S801","DOI":"10.1093\/infdis\/jix402","volume":"216","author":"S Bertagnolio","year":"2017","unstructured":"Bertagnolio S, et al. The World Health Organization\u2019s response to emerging Human Immunodeficiency Virus drug resistance and a call for global action. J Infect Dis. 2017;216(suppl_9):S801\u20134.","journal-title":"J Infect Dis"},{"key":"924_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292\u2013307.","journal-title":"Infect Genet Evol"},{"issue":"9553","key":"924_CR33","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(06)69861-9","volume":"368","author":"RD MacArthur","year":"2006","unstructured":"MacArthur RD, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST study): a long-term randomised trial. Lancet. 2006;368(9553):2125\u201335.","journal-title":"Lancet"},{"issue":"10","key":"924_CR34","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/aid.2011.0376","volume":"28","author":"Y Liu","year":"2012","unstructured":"Liu Y, et al. Identification of a novel HIV type 1 circulating recombinant form (CRF52_01B) in Southeast Asia. AIDS Res Hum Retroviruses. 2012;28(10):1357\u201361.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"924_CR35","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1089\/aid.2020.0151","volume":"36","author":"SQ Khairunisa","year":"2020","unstructured":"Khairunisa SQ, et al. 2018\u20132019 update on the molecular epidemiology of HIV-1 in Indonesia. AIDS Res Hum Retroviruses. 2020;36(11):957\u201363.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"924_CR36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1089\/aid.2020.0261","volume":"37","author":"AJ Bailey","year":"2021","unstructured":"Bailey AJ, Rhee SY, Shafer RW. Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons. AIDS Res Hum Retroviruses. 2021;37(10):736\u201343.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"924_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"924_CR38","doi-asserted-by":"publisher","first-page":"27739","DOI":"10.1038\/s41598-024-79449-1","volume":"14","author":"X Pang","year":"2024","unstructured":"Pang X, et al. Characteristics and influencing factors of immunological non-responders in HIV-1-infected patients receiving antiretroviral therapy: a cross-sectional study in Guangxi. Sci Rep. 2024;14(1):27739.","journal-title":"Sci Rep"},{"issue":"1","key":"924_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12879-024-09406-w","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study. BMC Infect Dis. 2024;24(1):514.","journal-title":"BMC Infect Dis"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00924-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00924-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00924-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:44:16Z","timestamp":1792086256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00924-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00924-y","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by the Medical Ethics Committee of the Guangxi Zhuang Autonomous Region Chest Hospital [Approval No.: 2024-S027-01]. All procedures were conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Participant confidentiality was maintained throughout the study, and all personal data were anonymized before analysis.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}